Merck & Co. (MRK) Shares Bought by Investment House LLC
Investment House LLC increased its position in Merck & Co. (NYSE:MRK) by 3.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,812 shares of the company’s stock after buying an additional 2,029 shares during the period. Investment House LLC’s holdings in Merck & Co. were worth $3,561,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. Raymond James Trust N.A. boosted its stake in shares of Merck & Co. by 3.3% in the second quarter. Raymond James Trust N.A. now owns 337,745 shares of the company’s stock valued at $19,457,000 after buying an additional 10,865 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Merck & Co. by 16.1% in the second quarter. Nordea Investment Management AB now owns 2,411,985 shares of the company’s stock valued at $138,954,000 after buying an additional 334,806 shares during the last quarter. Orbis Allan Gray Ltd purchased a new position in shares of Merck & Co. during the first quarter valued at approximately $239,761,000. Envestnet Asset Management Inc. increased its position in shares of Merck & Co. by 7.0% in the first quarter. Envestnet Asset Management Inc. now owns 1,107,242 shares of the company’s stock valued at $58,584,000 after buying an additional 72,808 shares during the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in shares of Merck & Co. during the second quarter valued at approximately $1,816,000. 72.93% of the stock is owned by institutional investors and hedge funds.
Merck & Co. (NYSE:MRK) traded down 0.59% during midday trading on Friday, reaching $62.14. 12,204,208 shares of the company were exchanged. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.86. The company has a market capitalization of $171.83 billion, a PE ratio of 34.09 and a beta of 0.68. The firm has a 50-day moving average price of $62.56 and a 200-day moving average price of $58.70.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings results on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The business had revenue of $9.84 billion for the quarter, compared to analysts’ expectations of $9.79 billion. During the same period in the prior year, the company posted $0.86 EPS. The business’s revenue for the quarter was up .6% on a year-over-year basis. Equities research analysts anticipate that Merck & Co. will post $3.75 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, October 7th. Stockholders of record on Thursday, September 15th were paid a dividend of $0.46 per share. The ex-dividend date was Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.96%. Merck & Co.’s dividend payout ratio (DPR) is presently 101.10%.
Several brokerages recently commented on MRK. Jefferies Group reiterated a “hold” rating and set a $65.00 price target on shares of Merck & Co. in a report on Sunday. Zacks Investment Research upgraded shares of Merck & Co. from a “hold” rating to a “buy” rating and set a $70.00 price target on the stock in a report on Friday. Bank of America Corp. upgraded shares of Merck & Co. from a “neutral” rating to a “buy” rating and upped their price target for the company from $57.00 to $70.00 in a report on Thursday. Leerink Swann reiterated a “market perform” rating and set a $65.00 price target on shares of Merck & Co. in a report on Wednesday. Finally, Barclays PLC reiterated an “overweight” rating on shares of Merck & Co. in a report on Wednesday. Twelve investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of €65.58 ($72.87).
In other news, insider Weir Mirian M. Graddick sold 40,800 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of €62.07 ($68.97), for a total transaction of €2,532,456.00 ($2,813,840.00). Following the transaction, the insider now directly owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,894,837.90). The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Kenneth C. Frazier sold 392,000 shares of the company’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the transaction, the chairman now directly owns 760,877 shares in the company, valued at €47,029,807.37 ($52,255,341.52). The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.